Doug Hampton

Ambulatory Polysomnography (PSG) Systems Market to Reach $570.7 Million, Globally, by 2031 at 6.0% CAGR: Allied Market Research

by

The expansion of the ambulatory polysomnography (PSG) systems market is heavily influenced by the incidence of various sleep disorders, which creates attractive prospects for market growth. The North America region is projected to garner the highest revenue by 2031. PORTLAND, Ore., May 15, 2023 /PRNewswire/ — Allied Market Research published a report, titled, “Ambulatory Polysomnography … Read more

Cascade Health Announces Venture Funding Round to Build Intelligent Platform for Healthcare Transparency

by

Company’s advanced generative AI-powered cloud platform creates clarity around healthcare pricing, coverage for consumers, employers, government agencies, hospitals, insurance companies and other businesses in the healthcare industry SEATTLE, May 15, 2023 /PRNewswire/ — Cascade Health, an intelligent platform for healthcare transparency, announced it has raised $1.7 million in venture funding led by AlleyCorp with participation … Read more

Survey Finds that Americans Know They Feel Their Best and Have Reduced Stress After Getting a Good Night’s Rest

by

Natrol is on a Mission This Mental Health Awareness Month to Help Consumers Break the Sleep Stress Cycle Through New “Wake Up Call” Campaign SHERMAN OAKS, Calif., May 15, 2023 /PRNewswire/ — A recent survey* of the Sleep Stress Cycle taken by 2,000 adults shows that 9 out of 10 (92%) agree they’re less stressed … Read more

Alliance Creative Group (ACGX) Reports First Quarter of 2023 Financials with Over $4,000,000 in assets

by

The transition for ACG is making progress in 2023 CHICAGO, May 15, 2023 /PRNewswire/ — Alliance Creative Group, Inc., (http://www.AllianceCreativeGroup.com) (Stock Symbol OTC: ACGX) is pleased to announce the results of Operations for the Three Months and Quarter Ending March 31, 2023. Revenues for the quarter ending March 31, 2023 (“Q1 2023”) were $845,676 Gross … Read more

Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update

by

TORRANCE, Calif., May 15, 2023 /PRNewswire/ — Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three months ended March 31, 2023. Recent Highlights “We enjoyed a fifth straight increase in … Read more

Lipella Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update

by

Successful top line results from Phase 2a clinical trial for lead candidate LP-10 Oral Health Scientific Advisory Board established to focus on development of LP-310 for oral lichen planus Late-breaking presentation of Phase 2a study results at the American Urological Association Annual Meeting Manufacturing collaboration agreement with Cook MyoSite in anticipation of Lipella’s forthcoming Investigational … Read more

NeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial

by

The primary efficacy endpoint of PARADIGM, (NCT05357950), is the assessment of ALS-biomarkers to evaluate PrimeC and its biological activity. Secondary endpoints include the clinical outcome measures Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R), Slow Vital Capacity (SVC), and overall survival, as well as safety and tolerability, in addition to a robust battery of additional biomarkers … Read more